Tatsuyuki Chiyoda

ORCID: 0000-0002-8214-2242 · 9 papers in corpus
case-report 2025
International cancer conference journal ·doi:10.1007/s13691-025-00795-6

We report the first documented case of primary ovarian clear cell carcinoma harboring an ETV6::NTRK3 fusion gene. A 49-year-old woman presented with a rapidly growing ovarian cyst that was diagnosed as stage IC1 clear cell carcinoma followi…

other 2025
Journal of gynecologic oncology ·doi:10.3802/jgo.2025.36.e104

OBJECTIVE: Medroxyprogesterone acetate (MPA) is an effective fertility-preserving treatment for early endometrial cancer and atypical endometrial hyperplasia (AEH), and rarely leads to the development of extrauterine lesions (ELs). We aimed…

lab-animal 2025
Cancer research communications ·doi:10.1158/2767-9764.crc-25-0024

UNLABELLED: There are currently no effective treatments available for clear cell ovarian cancer (CCC). In this study, we aimed to identify effective drugs for CCC through high-throughput drug screening (HTDS) using ovarian cancer organoids …

other 2025
Cancer medicine ·doi:10.1002/cam4.70601

BACKGROUND: Borderline ovarian tumors (BOTs) differ from ovarian carcinomas in their clinical presentation and behavior, yet their molecular characteristics remain poorly understood. This study aims to address this gap by integrating whole-…

other 2022

正常卵管3例、子宮内膜症(卵巣子宮内膜症性嚢胞)3例、卵巣癌(高異型度漿液性癌3例、明細胞癌3例)について質量分析を用いた解析を行った。正常卵管は高異型度漿液性癌の、子宮内膜症は明細胞癌のそれぞれ発症母地である。まずノンターゲットの脂質解析を行った。CE18.2、CE18.1、CE20.4、CE20.3、CE22.6、CE20.5、CE22.4、CE16.1、CE22.5、CE20.2、CE18.3の発現が正常卵管に比して子宮内膜症および卵巣癌では高かった。高異型度漿液性癌に…

other 2020
Cancer medicine ·doi:10.1002/cam4.3383

Precision medicine based on cancer genomics is being applied in clinical practice. However, patients do not always derive benefits from genomic testing. Here, we performed targeted amplicon exome sequencing-based panel tests, including 160 …

observational 2020
Scientific reports ·doi:10.1038/s41598-020-58066-8

Uterine leiomyoma is one of the most common gynaecologic benign tumours, but its genetic basis remains largely unknown. Six previous GWAS identified 33 genetic factors in total. Here, we performed a two-staged GWAS using 13,746 cases and 70…

lab-animal 2020
Scientific reports ·doi:10.1038/s41598-020-69488-9

The use of primary patient-derived organoids for drug sensitivity and resistance testing could play an important role in precision cancer medicine. We developed expandable ovarian cancer organoids in < 3 weeks; these organoids captured the …

case-report 2020
Gynecologic oncology reports ·doi:10.1016/j.gore.2020.100645

•Cervical cancer occurring in patients with OHVIRA syndrome is very rare.•This case reports on HPV-negative adenocarcinoma located in the nonvisible cervix.•Colposcopy and imaging are essential for cervical cancer with uterine malformation.…